Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | CTSV | O60911 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MYC | P01106 | 1/20 | 0.56 |
| ▸ | MAX | P61244 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625749 | 0.82 | MAPT (0.73) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL1531297 | 0.81 | MAPT (1.00) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL11870435 | 0.81 | MAPT (0.71) | MAPTCTSVCTSLKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL15054415 | 0.81 | MAPT (0.71) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL7846339 | 0.78 | MAPT (0.68) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL4249101 | 0.78 | CTSV (0.86) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL3279807 | 0.78 | MAPT (0.72) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL17434401 | 0.77 | MAPT (0.70) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL22720195 | 0.77 | CTSV (0.78) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL354532 | 0.77 | CTSV (1.00) | MAPTCTSVCTSLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | UCB PHARMA S.A. (BE) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAPT 4414/4885CTSV 2205/4885CTSL 3011/4885 |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAPT 4414/4885CTSV 2205/4885CTSL 3011/4885 |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAPT 4414/4885CTSV 2205/4885CTSL 3011/4885 |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAPT 4414/4885CTSV 2205/4885CTSL 3011/4885 |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAPT 4391/4885CTSV 2265/4885CTSL 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.